Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours

Masuko Katoh; Izuma Nakayama; Zev A Wainberg; Kohei Shitara; Masaru Katoh

doi:10.1002/ctm2.1736

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1736 DOI: 10.1002/ctm2.1736

COMMENTARY

Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours

Author information +

History +

PDF

Cite this article

Download citation ▾

Masuko Katoh, Izuma Nakayama, Zev A Wainberg, Kohei Shitara, Masaru Katoh. Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours. Clinical and Translational Medicine, 2024, 14(6): e1736 DOI:10.1002/ctm2.1736

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat Rev Clin Oncol. 2020;17(8):457-474.

[2]	Bradley RK, Anczuków O. RNA splicing dysregulation and the hallmarks of cancer. Nat Rev Cancer. 2023;23(3):135-155.

[3]	Katoh M, Loriot Y, Brandi G, Tavolari S, Wainberg ZA, Katoh M. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions. Nat Rev Clin Oncol. 2024;21(4):312-329.

[4]	Nakayama I, Qi C, Chen Y, Nakamura Y, Shen L, Shitara K. Claudin 18.2 as a novel therapeutic target. Nat Rev Clin Oncol. 2024;21(5):354-369.

[5]	Catenacci DVT, Rasco D, Lee J, et al. Phase I escalation and expansion study of bemarituzumab (FPA144) in patients with advanced solid tumors and FGFR2b-Selected gastroesophageal adenocarcinoma. J Clin Oncol. 2020;38(21):2418-2426.

[6]	Wainberg ZA, Kang YK, Lee KW, et al. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial. Gastric Cancer. 2024;27(3):558-570.

[7]	Pharmaceutical Technology. FDA denies approval for Astellas’ investigational gastric cancer drug. 2024. Available from:

[8]	Katoh M, Katoh M. Precision medicine for human cancers with Notch signaling dysregulation. Int J Mol Med. 2020;45(2):279-297.

[9]	Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 2009;33(5):591-601.

[10]	Türeci O, Koslowski M, Helftenbein G, et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011;481(2):83-92.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.